Company news
Bluenergies Ltd. (TSXV:BLU) news
Bluenergies Ltd. news releases on 6ix. Latest, Sep 14, 2026: BLUENERGIES ANNOUNCES ADVISORY AGREEMENTS
Press releases & updates
BLUENERGIES ANNOUNCES ADVISORY AGREEMENTS
September 13, 2026
BLUENERGIES ANNOUNCES CLOSING OF NON-BROKERED PRIVATE PLACEMENT OF UNITS FOR GROSS PROCEEDS OF C$20.7 MILLION
July 23, 2026
BLUENERGIES ANNOUNCES UPSIZE OF NON-BROKERED PRIVATE PLACEMENT OF UNITS FOR GROSS PROCEEDS OF UP TO C$20,700,000
July 21, 2026
BLUENERGIES ANNOUNCES NON-BROKERED PRIVATE PLACEMENT IS FULLY SUBSCRIBED
July 9, 2026
BLUENERGIES ANNOUNCES NON-BROKERED PRIVATE PLACEMENT OF UNITS FOR GROSS PROCEEDS OF UP TO C$10 MILLION
July 9, 2026
BLUENERGIES AND TOTALENERGIES PROGRESS OPERATIONS, HARPER BASIN, OFFSHORE LIBERIA
July 6, 2026
BLUENERGIES PROVIDES DETAILS OF INVESTOR RELATIONS ENGAGEMENTS
June 26, 2026
BLUENERGIES ANNOUNCES DTC ELIGIBILITY, ENGAGEMENT OF MARKET MAKER AND INITIATION OF RESEARCH COVERAGE
April 27, 2026
BLUENERGIES ANNOUNCES FINANCIAL ADVISORY AGREEMENTS WITH HAYWOOD SECURITIES INC. AND CANACCORD GENUITY CORP.
April 16, 2026
BLUENERGIES ANNOUNCES TRADING ON OTCQX BEST MARKET UNDER THE TRADING SYMBOL "BLUGF"
March 30, 2026
OTC Markets Group Welcomes BluEnergies Ltd. to OTCQX
March 30, 2026
BLUENERGIES SECURES TOP BID IN GULF OF AMERICA LEASE SALE, ENGAGES INDEPENDENT HOUSTON FIRM FOR RESERVE EVALUATION
March 19, 2026
BLUENERGIES ANNOUNCES ENGAGEMENT OF CURZIO RESEARCH, INC. AND APPOINTMENT OF DOUG ALLEN, SENIOR MANAGER OF INVESTOR RELATIONS
March 16, 2026
BLUENERGIES ANNOUNCES COMPLETION OF WARRANT ACCELERATION
March 12, 2026
BLUENERGIES ANNOUNCES WARRANT EXPIRY ACCELERATION
February 9, 2026
BLUENERGIES ANNOUNCES SHARES FOR SERVICES AND OPTION GRANT
January 16, 2026
TOTALENERGIES PARTNERS WITH BLUENERGIES IN ITS HARPER BASIN FAN PLAY, OFFSHORE LIBERIA
January 15, 2026
BLUENERGIES ANNOUNCES CEO TRANSITION
May 8, 2025
BLUENERGIES LTD. ANNOUNCES COMMENCEMENT OF TRADING ON THE TSX VENTURE EXCHANGE
April 14, 2025
BluEnrgies Ltd. (Formerly Acme Gold Company Limited) Announces Closing of Reverse Takeover Transaction
April 9, 2025
Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health
June 28, 2023
S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite Index and S&P/TSX 60 Index
September 2, 2022
IIROC Trade Resumption - BLU
December 13, 2021
IIROC Trading Halt - BLU
December 13, 2021
BELLUS Health to Present at Two Upcoming Healthcare Investor Conferences
April 4, 2019
BELLUS Health Announces Clearance of U.S. IND for BLU-5937 Phase 2 Study in Chronic Cough Patients
April 3, 2019
BELLUS Health Presents 2018 Highlights and 2019 Corporate Plan
February 21, 2019
BELLUS Health Updates BLU-5937 Top-Line Phase 1 Results Timeline to November 2018
November 14, 2018
BELLUS Health Announces Issuance of New U.S. Patent Claiming P2X3 Selectivity as a Means of Minimizing Taste Effects for its Lead Chronic Cough Drug Candidate BLU-5937
October 31, 2018
BELLUS Health Announces Appointment of Clinical Advisory Board
September 25, 2018
BELLUS Health to Present at Baird 2018 Global Healthcare Conference
August 30, 2018
BELLUS Health Reports Financial and Operating Results for the Second Quarter Ended June 30, 2018
August 8, 2018
BELLUS Health Announces Patent Protection Secured in All Major Pharmaceutical Markets for Lead Drug Candidate BLU-5937
July 19, 2018
BELLUS Health Initiates Phase 1 Clinical Study for its Chronic Cough Drug Candidate, BLU-5937
July 9, 2018
BELLUS Health Presents BLU-5937 Preclinical Data and Updated Phase 1 Timeline at 2018 International Cough Symposium
June 27, 2018
BELLUS Health to Present at the 2018 International Cough Symposium
June 20, 2018
BELLUS Health Reports Financial and Operating Results for the First Quarter Ended March 31, 2018
May 15, 2018
BELLUS Health Responds to Recent Share Price Appreciation and Increased Trading Activity
April 30, 2018
BELLUS Health to Present at Bloom Burton & Co. Healthcare Investor Conference
April 26, 2018
BELLUS Health Reports Financial and Operating Results for the Year Ended December 31, 2017
February 21, 2018
BELLUS Health Receives Milestone Payment from Taro Pharmaceuticals
January 9, 2018
BELLUS Health to Present at Biotech Showcase(TM) 2018 Conference
January 4, 2018
BELLUS Health Closes $20M Common Share Financing
December 12, 2017
IIROC Trade Resumption - BELLUS Health Inc.
December 5, 2017
IIROC Trade Halt - BELLUS Health Inc.
December 5, 2017
BELLUS Health Announces Pricing of up to $20M Equity Offering
December 5, 2017
BELLUS Health Announces Overnight Marketed Equity Offering
December 4, 2017
BELLUS Health Reports Financial and Operating Results for the Third Quarter Ended September 30, 2017
November 8, 2017
BELLUS Health Appoints Dr. Clarissa Desjardins to its Board of Directors
September 27, 2017
BELLUS Health Chronic Cough Webcast Taking Place Today
September 20, 2017